Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-10-21
CAR-T Cell Therapy Active Trials in China
As of 2026-10-21, there are 13 active clinical trials investigating CAR-T Cell Therapy for multiple myeloma across 22 provinces and 59 study centers in China. Chimeric Antigen Receptor T-cell (CAR-T) therapy genetically engineers patient T cells to target myeloma antigens such as BCMA and GPRC5D, delivering deep and durable responses in relapsed/refractory myeloma.
Active Trials
13
Provinces
22
Centers
59
Active Studies (13)
Population synthesized by CMDNShowing 13 published English records of 13 registry trials.
Phase INCT06644118
RecruitingAn Early Exploratory Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Dual-target CAR-T cell therapy targeting GPRC5D and BCMA
Study Sites: Beijing Gobroad Hospital
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Target Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Phase I/IIaCTR20233309
RecruitingA Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital、Henan Cancer Hospital 等 10 家中心
Phase IICTR20230238
RecruitingA Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA-targeted CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、Affiliated Hospital of Hebei University 等 25 家中心
Phase IIICTR20241656
RecruitingA Randomized Controlled Phase III Clinical Study of Equecabtagene Autoleucel Injection in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Peking Union Medical College Hospital, Chinese Academy of Medical Sciences 等 28 家中心
Phase ICTR20243438
RecruitingA Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA-targeting CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Phase I
RecruitingA Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
Study Sites: Cancer Hospital Chinese Academy of Medical Sciences
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase ICTR20240189
RecruitingA Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of SWK001 in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: The First Affiliated Hospital of USTC
Phase I
RecruitingAn Early Exploratory Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Target Population: Relapsed/refractory
Target: CD19, BCMA dual-target in vivo CAR-T
Study Sites: Chinese PLA General Hospital (301 Hospital)
Phase Ib/IICTR20232814
RecruitingAn Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Target Population: Relapsed/refractory
Target: GPRC5D-targeted CAR-T
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 8 家中心
Early Exploratory Clinical StudyNCT07715630
RecruitingIn Vivo-Generated PICX Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Relapsed/refractory multiple myeloma (RRMM)
Study Sites: The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Phase Ib/IICTR20221467
RecruitingA Phase Ib/II Clinical Study of CBM.BCMA Chimeric Antigen Receptor T-cell Injection (C-CAR088) in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous anti-BCMA CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)